Long-term follow-up of patients with pulmonary hypertension after catheter ablation of atrial fibrillation and atrial tachycardia
Frontiers in Cardiovascular Medicine · 18.06.2026 · 13
DOI: 10.3389/fcvm.2026.1826752 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 18.06.2026. Verfasst von Milan Dusik und 10 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Medicine-Department of Cardiovascular Medicine of the 1st Faculty of Medicine and General University Hospital in Prague, Prague, Cz…. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky.
Abstract (Originalsprache)
Introduction
The previously published randomized trial comparing an extensive (targeting both clinical arrhythmia and bi-atrial arrhythmogenic substrate) and a limited (clinical arrhythmia only) approach to catheter ablation in patients with pulmonary hypertension did not demonstrate a significant difference in atrial tachyarrhythmia (ATA) recurrence during the one-year follow-up. This study presents the long-term results of these patients.
Methods
Participants enrolled in the randomized trial (NCT04053361) were further followed and checked for ATA recurrence and all-cause mortality. Follow-up was primarily clinically driven, as the protocol for this secondary analysis was not fully prespecified Results A total of 74 patients [41 males, median age 71 years (IQR: 61; 75)] were randomized to the extended ( N = 36) and limited ( N = 38) ablation groups and followed for a median of 45 and 41 months, respectively. The ATAs recurred in 22 (61%) patients after extended vs. 19 (50%) patients after limited ablation [hazard ratio (HR) 1.22, 95% confidence interval (CI): 0.66–2.3]. There were 21 (58%) deaths in the extended ablation group, and 22 (58%) patients died during follow-up after the limited ablation (HR: 0.74, 95% CI: 0.39–1.4). No recurrence of typical atrial flutter was noted among the 23 patients treated by the ablation of the cavo-tricuspid isthmus.
Conclusion
Extensive catheter ablation in patients with pulmonary hypertension did not reduce ATA recurrence during the routine follow-up of more than 40 months. Cavo-tricuspid isthmus ablation appears effective in preventing recurrence of typical atrial flutter, even in this high-risk population. Given the exploratory nature of these analyses, further research is needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 2nd Department of Medicine-Department of Cardiovascular Medicine of the 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czechia.
- First Department of Internal Medicine-Cardiology, Olomouc University Hospital, Olomouc, Czechia.
- Department of Cardiology, Institute of Clinical and Experimental Medicine, Prague, Czechia.
Förderung
- Ministerstvo Zdravotnictví Ceské Republiky
Zitieren
APA
Dusik, M., Havranek, S., Fingrova, Z., Jansa, P., Ambroz, D., Dytrych, V., Skala, T., Hutyra, M., Precek, J., Reichenbach, A., & Wichterle, D. (2026). Long-term follow-up of patients with pulmonary hypertension after catheter ablation of atrial fibrillation and atrial tachycardia. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1826752
Vancouver
Dusik M, Havranek S, Fingrova Z, Jansa P, Ambroz D, Dytrych V, et al. Long-term follow-up of patients with pulmonary hypertension after catheter ablation of atrial fibrillation and atrial tachycardia. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1826752
BibTeX
@article{Dusik2026,
author = {Dusik, Milan and Havranek, Stepan and Fingrova, Zdenka and Jansa, Pavel and Ambroz, David and Dytrych, Vladimir and Skala, Tomas and Hutyra, Martin and Precek, Jan and Reichenbach, Adrian and Wichterle, Dan},
title = {Long-term follow-up of patients with pulmonary hypertension after catheter ablation of atrial fibrillation and atrial tachycardia},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.1826752}
}
EUVIMED